Skip to Main Content

Author Details

Nora M Navone
MD Anderson Cancer Center
1987
139
49
PMIDPaper TitleJournal TitlePublished Year
36100698Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones.Prostate Cancer Prostatic Dis2023
38049604Prostate lineage-specific metabolism governs luminal differentiation and response to antiandrogen treatment.Nat Cell Biol2023
37930121Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer.Cancer Res Commun2023
37815914MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer.Cell Rep2023
37018402ETV4 mediates dosage-dependent prostate tumor initiation and cooperates with p53 loss to generate prostate cancer.Sci Adv2023
36650259The future of patient-derived xenografts in prostate cancer research.Nat Rev Urol2023
36461624A 3D Perfusable Platform for In Vitro Culture of Patient Derived Xenografts.Adv Healthc Mater2023
34774481Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer.Eur Urol Oncol2022
35805010Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) Components.Cancers (Basel)2022
35565211Bone Progenitors Pull the Strings on the Early Metabolic Rewiring Occurring in Prostate Cancer Cells.Cancers (Basel)2022
35385726Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis.Cell Rep2022
34937944Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer.Nature2022
35204174Exploiting Interdata Relationships in Prostate Cancer Proteomes: Clinical Significance of HO-1 Interactors.Antioxidants (Basel)2022
33279304Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies.Eur Urol2021
33824525Optimizing the diagnosis and management of ductal prostate cancer.Nat Rev Urol2021
33483585The expression of YWHAZ and NDRG1 predicts aggressive outcome in human prostate cancer.Commun Biol2021
33753455Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment.Clin Cancer Res2021
34738088Autophagy Inhibition by Targeting PIKfyve Potentiates Response to Immune Checkpoint Blockade in Prostate Cancer.Nat Cancer2021
34584218Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel.Oncogene2021
34636746Inhibition of GATA2 in prostate cancer by a clinically available small molecule.Endocr Relat Cancer2021
34208670HO-1 Modulates Aerobic Glycolysis through LDH in Prostate Cancer Cells.Antioxidants (Basel)2021
32369771Fibroblast growth factors signaling in bone metastasis.Endocr Relat Cancer2020
31861963Heme Oxygenase-1 Is a Pivotal Modulator of Bone Turnover and Remodeling: Molecular Implications for Prostate Cancer Bone Metastasis.Antioxid Redox Signal2020
31941830A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer.Clin Cancer Res2020
33346184Enhanced Viability for Ex vivo 3D Hydrogel Cultures of Patient-Derived Xenografts in a Perfused Microfluidic Platform.J Vis Exp2020
32576626The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development.Clin Cancer Res2020
32640729Myxovirus Resistance Protein 1 (MX1), a Novel HO-1 Interactor, Tilts the Balance of Endoplasmic Reticulum Stress towards Pro-Death Events in Prostate Cancer.Biomolecules2020
32197509HO-1 Interactors Involved in the Colonization of the Bone Niche: Role of ANXA2 in Prostate Cancer Progression.Biomolecules2020
30532030Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition.Oncogene2019
31446281Pseudogene Associated Recurrent Gene Fusion in Prostate Cancer.Neoplasia2019
30920960ERR1 and PGC1α associated mitochondrial alterations correlate with pan-cancer disparity in African Americans.J Clin Invest2019
30858546Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancer.Oncogene2019
30682644Engineered bone for probing organotypic growth and therapy response of prostate cancer tumoroids in vitro.Biomaterials2019
29138344Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.Clin Cancer Res2018
29887238FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer.Urol Oncol2018
30073676Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.Prostate2018
30068572Intravital microscopy of osteolytic progression and therapy response of cancer lesions in the bone.Sci Transl Med2018
30555629The estrogen receptor variants β2 and β5 induce stem cell characteristics and chemotherapy resistance in prostate cancer through activation of hypoxic signaling.Oncotarget2018
29769196An <i>In Vivo</i> Screen Identifies PYGO2 as a Driver for Metastatic Prostate Cancer.Cancer Res2018
29396431Game-changing restraint of Ros-damaged phenylalanine, upon tumor metastasis.Cell Death Dis2018
28512172<i>In Vivo</i> Hemin Conditioning Targets the Vascular and Immunologic Compartments and Restrains Prostate Tumor Development.Clin Cancer Res2017
28228262Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.Cell Rep2017
28166537Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer.Nature2017
26096936Hyperactivated FRS2α-mediated signaling in prostate cancer cells promotes tumor angiogenesis and predicts poor clinical outcome of patients.Oncogene2016
26599623A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions.Biomaterials2016
27791181Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer.Proc Natl Acad Sci U S A2016
28032857Heme oxygenase-1 in the forefront of a multi-molecular network that governs cell-cell contacts and filopodia-induced zippering in prostate cancer.Cell Death Dis2016
26890396Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas.Epigenetics2016
26806347Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer.Neoplasia2016
26792867BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer.Mol Cancer Res2016
  • 1 - 50 of 139

Recommended Authors

Brian W Simons
Center for Comparative Medicine, Baylor College of Medicine
Career Start Year 2008
Number of shared co-authors 3
Antonio Hurtado-Coll
University of British Columbia
Career Start Year 2002
Number of shared co-authors 13
Ladan Fazli
University of British Columbia
Career Start Year 2002
Number of shared co-authors 20
Ilsa Coleman
Fred Hutchinson Cancer Center
Career Start Year 2001
Number of shared co-authors 23
Jiaoti Huang
Duke University School of Medicine
Career Start Year 2000
Number of shared co-authors 22
Phillip G Febbo
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 13
Volker Jung
Clinic of Urology and Pediatric Urology, University of Saarland
Career Start Year 1994
Number of shared co-authors 0
Ganesh V Raj
University of Texas Southwestern Medical Center at Dallas
Career Start Year 1994
Number of shared co-authors 12
Isla P Garraway
David Geffen School of Medicine University of California Los Angeles
Career Start Year 1993
Number of shared co-authors 12
Edwin M Posadas
Cedars-Sinai Medical Center
Career Start Year 1993
Number of shared co-authors 16
Rosina T Lis
National Cancer Institute
Career Start Year 1992
Number of shared co-authors 26
Marshall Scott Lucia
University of Colorado School of Medicine
Career Start Year 1991
Number of shared co-authors 4
Bruce Montgomery
Fred Hutchinson Cancer Center, University of Washington
Career Start Year 1990
Number of shared co-authors 27
Christopher M Hovens
Royal Melbourne Hospital, The University of Melbourne
Career Start Year 1989
Number of shared co-authors 4
Christopher P Evans
University of California Davis
Career Start Year 1988
Number of shared co-authors 19
Adrie van Bokhoven
University of Colorado Anschutz Medical Campus
Career Start Year 1988
Number of shared co-authors 0
Tapio Visakorpi
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 1987
Number of shared co-authors 13
Michael R Freeman
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Career Start Year 1987
Number of shared co-authors 10
Martin E Gleave
University of British Columbia
Career Start Year 1987
Number of shared co-authors 30
Anders Bjartell
Skane University Hospital, Lund University
Career Start Year 1987
Number of shared co-authors 22
Beatrice S Knudsen
University of Utah
Career Start Year 1986
Number of shared co-authors 18
Massimo Loda
Weill Medical College of Cornell University
Career Start Year 1984
Number of shared co-authors 31
David M Nanus
Sandra and Edward Meyer Cancer Center
Career Start Year 1983
Number of shared co-authors 31
George Steven Bova
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 1982
Number of shared co-authors 6
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Career Start Year 1981
Number of shared co-authors 31
Lawrence D True
University of Washington School of Medicine
Career Start Year 1980
Number of shared co-authors 32
William B Isaacs
The Brady Urological Institute, The Johns Hopkins School of Medicine
Career Start Year 1979
Number of shared co-authors 20
Christopher S Foster
The Institute of Cancer Research
Career Start Year 1978
Number of shared co-authors 4
Ralph Buttyan
University of British Columbia
Career Start Year 1976
Number of shared co-authors 9
Howard I Scher
Memorial Sloan Kettering Cancer Center
Career Start Year 1973
Number of shared co-authors 27

Collaborators

Eleni Efstathiou
Houston Methodist Cancer Center
Co-authored papers 17
Arul M Chinnaiyan
University of Michigan Medical School.
Co-authored papers 10
Xuhong Cao
Michigan Center for Translational Pathology.
Co-authored papers 6
Wadih Arap
Rutgers Cancer Institute of New Jersey
Co-authored papers 5
Renata Pasqualini
Rutgers Cancer Institute of New Jersey
Co-authored papers 5
Wei Zhang
The University of Texas MD Anderson Cancer Center
Co-authored papers 5
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 4
Mary C Farach-Carson
The University of Texas Health Science Center at Houston School of Dentistry
Co-authored papers 4
Yuzhuo Wang
University of British Columbia
Co-authored papers 3
Kenneth J Pienta
The Brady Urological Institute, Johns Hopkins University School of Medicine
Co-authored papers 3
Eva Corey
University of Washington School of Medicine
Co-authored papers 3
Nallasivam Palanisamy
Vattikuti Urology Institute
Co-authored papers 3
Wouter H P Driessen
The University of Texas M.D. Anderson Cancer Center
Co-authored papers 3
Javed Siddiqui
Michigan Center for Translational Pathology, University of Michigan ann arbor
Co-authored papers 3
Richard L Sidman
Harvard Medical School
Co-authored papers 3
Scott A Tomlins
Rogel Cancer Center, University of Michigan Medical School ann arbor
Co-authored papers 3
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Co-authored papers 3
Pei Lin
Co-authored papers 2
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Co-authored papers 2
Paul C Boutros
University of California los angeles
Co-authored papers 2
Lakshmi P Kunju
Michigan Center for Translational Pathology, University of Michigan ann arbor
Co-authored papers 2
Robert J Lonigro
Michigan Center for Translational Pathology, University of Michigan ann arbor
Co-authored papers 2
Robert L Vessella
University of Washington
Co-authored papers 2
Preston D Crowell
University of California los angeles
Co-authored papers 2
Yaoqi Alan Wang
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Shoudan Liang
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
David C Smith
Rogel Comprehensive Cancer Center, University of Michigan ann arbor
Co-authored papers 2
Ganiraju C Manyam
the University of Texas MD Anderson Cancer Center
Co-authored papers 2
Fernanda I Staquicini
Rutgers Cancer Institute of New Jersey
Co-authored papers 2
David Cogdell
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Release 1.2